Seeking Alpha

Jason Aycock

Jason Aycock
Send Message
View as an RSS Feed
View Jason Aycock's Comments BY TICKER:
Latest  |  Highest rated
  • WEB.COM (WWWW): Q3 EPS of $0.41 beats by $0.02. Revenue of $124.2M beats by $0.7M. Shares +2.1% AH. (PR[View news story]
    This item's been adjusted to note that non-GAAP revenue (adding back a fair-value adjustment to acquired deferred revenue) of $124.2M beat analysts' expectations as well as the company's.
    Oct 26 11:44 AM | Likes Like |Link to Comment
  • Hercules Offshore (HERO): Q3 EPS of -$0.10 misses by $0.01. Revenue of $184.9M (+14% Y/Y) beats by $1.5M. (PR[View news story]
    We've adjusted this item to account for non-GAAP measures (impairment of Hercules 252 and 258; gain from sale of Platform Rig 3, insurance settlement on Hercules 185 that were pretax items).
    Oct 25 08:45 AM | Likes Like |Link to Comment
  • Insurers are taking an even more cautious stance on Questcor's (QCOR -4.1%) Acthar, according to a Citron Research report. The short seller is now claiming that Humana (HUM -1.5%) has issued a new Commercial Preauthorization document containing a new, specifically asterisked preauthorization for reimbursement for Acthar, which it contends is part of a pattern of insurers taking a more restrictive stance on authorization policy with regard to the drug's reimbursement. [View news story]
    A few things about this.

    For those saying they want to read the relevant docs and make up their own mind -- the claim and the Humana doc are prominently linked above so you can do so. That's the best outcome of an item like this: You're informed about something that might be moving the stock, and are able to see for yourself whether there's anything to it.

    Many of us have noted that Citron is publishing bearish reports this week, and the stock is moving off of that. This item alerted investors to the Friday occurrence of that, nothing more. That's not "associating with" or "endorsing" a point of view on buying or selling; let's be clear about that. Market Currents is an alerts-based feature; the alternative would be just leaving investors to their own devices to find out what's up with QCOR on Friday?

    I think if you're long, you welcome the opportunity to see for yourself what's going on -- if anything -- and then have a platform from which to respond/refute ... whether in a long comment thread, or an instablog or article of your own.

    Heading into earnings I'm looking forward to information from involved investors like some of you to shed some light on the details of preauthorization and enrollment-period changes and make your own case for (or against) the stock.
    Oct 20 03:24 PM | Likes Like |Link to Comment
  • Insurers are taking an even more cautious stance on Questcor's (QCOR -4.1%) Acthar, according to a Citron Research report. The short seller is now claiming that Humana (HUM -1.5%) has issued a new Commercial Preauthorization document containing a new, specifically asterisked preauthorization for reimbursement for Acthar, which it contends is part of a pattern of insurers taking a more restrictive stance on authorization policy with regard to the drug's reimbursement. [View news story]
    Folks, regarding any factual dispute here, this item states that Citron is pointing to the new Humana doc, and that Citron is claiming (not proving) that this means a tighter stance on authorization. The Market Current notes Citron is a short seller.

    Is any of that in dispute?
    Oct 19 07:24 PM | Likes Like |Link to Comment
  • Bernanke: No new stimulus measures are outlined, but as usual, he says the Fed stands ready to act as needed. The cost of non-traditional policies (QE) "appear manageable." The economy is "far from satisfactory," and labor market stagnation creates enormous suffering. [View news story]
    I don't disagree here ... but it reminds me of what people said before: "Whattaya crazy, he's not gonna act now, he'll make a move at Jackson Hole!"
    Aug 31 10:15 AM | Likes Like |Link to Comment
  • THQ (THQI): FQ1 EPS of -$3.41 beats by $0.56. Revenue of $38.5M (+33.5% Y/Y) beats by $9M. (PR)  [View news story]
    Adjusted this item to reflect the non-GAAP net sales they are reporting of $38,525,000 (Bigger beat on revenue). GAAP revenue of $133.7M was reduced by deferred revenue impact of $95.2M.
    Aug 6 06:03 PM | Likes Like |Link to Comment
  • More from the Netflix (NFLX) Q2: expects Q3 EPS of -$0.10 to $0.14 vs. $0.11. Guides lower for net domestic subscription additions this quarter in part due to Olympics. Domestic streaming sub additions of 530K to total 23.94M; international stream sub additions of 560K to total 3.62M. Domestic DVD net subscription losses of 850K, bringing those subs to 9.24M. Shares -14.3% AH.  [View news story]
    What they say specifically:

    "For Q3 quarter-to-date, our domestic net additions are very nearly the same as Q3 2010 over the comparable partial period. In that quarter two years ago, we finished with 1.8 million domestic net additions. However, in the middle of that quarter, we launched Netflix on the iPhone to great reception, and we don’t have an equivalent launch this quarter. Moreover, this quarter the Olympics are likely to have a negative impact on Netflix viewing and sign-ups. So, our Q3 guidance is 1 million to 1.8 million domestic net adds. If we finish Q3 in the high end of that range, we would remain on track for 7 million domestic net additions for the year; otherwise it would be challenging to achieve that goal by year end. In either case, we are generating impressive growth this year in our most developed market."
    Jul 24 04:30 PM | Likes Like |Link to Comment
  • More on the Moody's banking downgrades: A three-notch cut for CS. Two-notch rating cuts for JPM, C, MS, GS; just one notch for BAC. After hours: MS +3.7%; JPM +1%; BAC +1%; C +0.6%. (full statement)  [View news story]
    MS shareholders, for example, had baked in a three-notch cut today, so they're seen as coming off light.
    Jun 21 05:37 PM | 4 Likes Like |Link to Comment
  • After 74 years, another venerable Wall Street name - Smith Barney - is falling by the wayside, as Morgan Stanley plans to rename it Morgan Stanley Wealth Management. MS is in a multi-year process to buy the unit from Citigroup.  [View news story]
    YouTube covers the Smith Barney memory hole: http://bit.ly/Lkl4aZ
    Jun 12 02:00 PM | Likes Like |Link to Comment
  • Apr. Personal Income and Outlays: Income +0.2% vs. +0.3% expected, +0.4% prior. Personal spending +0.3% vs. +0.3% expected, +0.3% prior. PCE core price index +0.1% m/m vs. +0.2% expected, +0.2% prior.  [View news story]
    Had the Y/Y mixed up with M/M ... it's right now, at +0.1%.
    Jun 1 09:15 AM | Likes Like |Link to Comment
  • And now to the rescue: Chesapeake Energy (CHK) says it's gotten a $3B unsecured loan from Goldman Sachs and Jefferies Group, to be repaid from those 2012 asset sales.  [View news story]
    And more info likely to come on an 8:30 a.m. conference call Monday
    May 11 07:34 PM | 1 Like Like |Link to Comment
  • And now to the rescue: Chesapeake Energy (CHK) says it's gotten a $3B unsecured loan from Goldman Sachs and Jefferies Group, to be repaid from those 2012 asset sales.  [View news story]
    This much from clicking through:
    "The new facility, which ranks pari passu to Chesapeake's outstanding senior notes, matures on December 2, 2017 and may be repaid at any time this year without penalty at par value and carries an initial variable annual interest rate through December 31, 2012 of LIBOR plus 7.0%, which is currently 8.5%, given the 1.5% LIBOR floor in the loan agreement. During the remainder of the year, Chesapeake plans to complete asset sales totaling $9.0-$11.5 billion and intends to use a portion of the proceeds from these asset sales to repay the loan. Chesapeake has received strong interest from prospective buyers of its Permian Basin asset sales process and its Mississippi Lime joint venture process, and the company expects to complete these two transactions in the 2012 third quarter. "
    May 11 07:33 PM | 8 Likes Like |Link to Comment
  • Mobile payments juggernaut Square says it's now handling $5B (annualized) in transactions, up from $4B just a month ago and $2B in October. Square, said to be seeking funding at a $4B valuation, is popular with small businesses not only because of its low fee and ease-of-use, but also its ability to pay merchants within a day of a purchase, compared with 2-5 days for regular credit-card payments. PayPal Here has its work cut out for it.  [View news story]
    Thanks for noting; we clarified this item to note this is their annualized rate.
    Apr 25 11:26 PM | Likes Like |Link to Comment
  • Alexion (ALXN +1.8%) bounces back today after slipping despite a strong earnings report yesterday. Jefferies ups its price target from $68 to $76 on the shares, saying that sales of its marquee drug Soliris were higher than expected. Canaccord agrees, noting that the stock is a solid earnings execution story.  [View news story]
    Because their analyst isn't bullish on the stock ... they switched from Buy to Hold late 2010, and they set price targets below the trading price more than a year ago.

    They did raise the target on valuation, but it seems like other firms like Canaccord are much more bullish with aggressive targets.
    Apr 25 11:24 PM | Likes Like |Link to Comment
  • Goldman is pounding the table on Blackstone Group (BX -1.4%), calling on investors to take advantage of recent weakness to buy the shares despite reporting weak numbers earlier this week. The firm attributes the selloff to a reduced appetite for private equity, but notes that BX's business is strongly diversified and its credit business is poised for growth.  [View news story]
    Yes, the second reference linked to BK and caused it to alert in error. Thanks for calling to our attention.
    Apr 21 02:21 AM | Likes Like |Link to Comment
COMMENTS STATS
107 Comments
68 Likes